Troy Cox
CIK 1696923 · Executive Chair · last filed 2026-07-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FMI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
C/O FOUNDATION MEDICINE, INC., 150 SECON
CAMBRIDGE, MA 02141
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MPLT | Director | 23,484 | $7.43 | $174.6K | $148.7K | 2 | 2026-07-28 |
| LAB | Director | 475,702 | $0.70 | $334.2K | $0 | 7 | 2026-06-23 |
| SOPH | Director | 328,743 | $7.53 | $2.47M | $0 | 1 | 2026-06-22 |
| ZYME | Director | 7,500 | $30.69 | $230.2K | $348.8K | 6 | 2024-12-12 |
| SomaLogic, Inc. (SLGCW) Delisted | Executive Chair | 106,930 | $0.09 | $9.2K | $0 | 5 | 2023-03-22 |
| Foundation Medicine, Inc. (FMI) Delisted | Chief Executive Officer | 242,068 | — | — | -$3.33M | 7 | 2018-07-05 |
Recent Filings · Page 3 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-12 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2020-01-28 | ZYME | Buy (P) | +7,500 | $348.8K | EDGAR |
| 2018-08-02 | — | Mixed | −242,068 | -$33.16M | |
| 2018-07-05 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −1,402 | -$191.6K | EDGAR |
| 2018-05-17 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −2,157 | -$166.3K | EDGAR |
| 2018-05-09 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −7,063 | -$494.5K | EDGAR |
| 2018-04-03 | Foundation Medicine, Inc. (FMI) Delisted | Grant (A) | +37,357 | $2.94M | EDGAR |
| 2018-02-20 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −9,012 | -$605.8K | EDGAR |
| 2018-02-09 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −26,713 | -$1.87M | EDGAR |
| 2017-02-08 | Foundation Medicine, Inc. (FMI) Delisted | Grant (A) | +251,058 | $4.75M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.